JPMorgan and B. Riley Set Praxis Targets Above $700 as Dual FDA Decisions Approach
JPMorgan lifts Praxis target to $725; B. Riley starts at $713. Both see strong upside as two potential approvals approach in the next 10 weeks.
JPMorgan lifts Praxis target to $725; B. Riley starts at $713. Both see strong upside as two potential approvals approach in the next 10 weeks.
Analyst sees approvable assets and places stock on Positive Catalyst Watch.
Strong outlook for ulixacaltamide and relutrigine approvals by early 2027.
Phase 2 data showed 77% seizure reduction and sustained benefits up to 1 year.
BofA initiates coverage on IMMX with a Buy rating and $27 price target. RBC starts PRAX with Outperform ($449 PT), while Cantor begins coverage on RNA. Morgan Stanley downgrades ENGN to Underweight.
Praxis Precision Medicines stock jumps as Food and Drug Administration reviews new tremor drug showing strong results and safety.